CDMO Firms Set to Sustain Outperformance Amid Multiple Growth Drivers

Indian CDMO Sector Poised for Continued Growth Amid Rising Demand

The contract development and manufacturing organization (CDMO) sector in India is set to maintain its impressive performance trajectory, driven by robust growth drivers and increasing global demand.

Strong Performance Amid Market Volatility

The Indian pharma and healthcare indices have shown resilience, outperforming broader benchmarks with a return of approximately 20% over the past six months. Within this landscape, CDMO firms have emerged as standout performers. Notably, Laurus Labs has achieved a staggering 90% return, while the top five CDMO players, generating at least 40% of their revenue from this segment, have collectively posted an average return exceeding 60% during the same period.

This outperformance can be attributed to the rising trend of outsourcing and supply-chain rebalancing among global pharmaceutical and biotech companies, which are increasingly turning to Indian CDMOs for their manufacturing needs. As these companies seek to optimize costs and enhance efficiency, the demand for CDMO services is expected to rise significantly.

Growth Drivers for the CDMO Sector

Looking ahead, brokerages are optimistic about the growth momentum in the CDMO sector. Factors such as an increasing share of biologics funding, a healthy pipeline of biosimilar opportunities, and rising demand for peptide-based drugs are expected to propel the sector forward. Recent reports indicate that the CDMO sector has recorded double-digit year-on-year revenue growth in Q1 FY27, underscoring the sustained strength of underlying demand.

Despite some companies facing temporary challenges due to customer destocking and product attrition, the overall outlook remains positive. The sector is anticipated to benefit from improved capacity utilization levels and ongoing capacity expansion initiatives, which will enhance operational efficiency and profitability.

Valuation Concerns and Market Outlook

While the growth prospects for the CDMO sector are robust, potential investors should be mindful of valuation concerns. The average price-to-earnings ratio for top players stands at 66 times FY27 earnings, reflecting a market that has already factored in significant growth expectations following a sharp rally. This could temper future returns, particularly if growth does not meet these elevated expectations.

Moreover, as the global CDMO market is projected to grow from $140-145 billion to approximately $22-25 billion by 2035, Indian players are well-positioned to capture a larger share of this expanding market. The ongoing trend of supply-chain diversification, particularly in light of recent geopolitical developments, is likely to further bolster the demand for Indian CDMO services.

Key Players and Investment Sentiment

Divi’s Laboratories continues to be a favored choice among investors, with several brokerages highlighting its strong margins and stable performance. Other notable players include Laurus Labs and Sai Life Sciences, which are expected to benefit from increasing global outsourcing and differentiated technology platforms. However, both Divi’s and Syngene International are trading at relatively high valuations, which may warrant caution for prospective investors.

As the CDMO sector evolves, the focus will increasingly shift towards execution excellence and the successful commercialization of past investments. The ability to adapt to changing market dynamics and leverage new opportunities will be crucial for sustained growth in this competitive landscape.

Key Highlights

• CDMO sector outperformed broader market indices with average returns exceeding 60%.
• Laurus Labs led the way with a remarkable 90% return over the past six months.
• Rising outsourcing trends and supply-chain rebalancing are key growth drivers.
• Valuation concerns may temper future returns, with average P/E ratios at 66 times FY27 earnings.
• Divi’s Laboratories remains a top pick, alongside Laurus Labs and Sai Life Sciences.

Investor Note: The Indian CDMO sector presents compelling growth opportunities, but investors should remain vigilant regarding valuations and market dynamics. A focus on companies with strong operational capabilities and a clear growth strategy will be essential for navigating this evolving landscape.